LLY at a glance
Lilly (Eli) (LLY, SEC CIK 59478) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as September 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Lilly (Eli) (LLY) reported revenue of $65.2 billion (up 44.7% from FY2024) and net income of $20.6 billion. Diluted EPS was $22.95.
- As of June 30, 2026, 75 institutional investment managers tracked by SignalX reported holding Lilly (Eli) (LLY) shares worth $439.7 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Jonsson Patrik on August 17, 2026 of 6,500 shares at $1175.10 per share.
- In the last 90 days, LLY insiders reported 0 open-market purchases ($0) and 3 open-market sales ($16.0M) on Form 4, a net sale of $16.0M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $65.2B
- +44.7% vs prior year
- Insiders · 90 days
- 0 buys · 3 sells
- Net −$16.0M
- 13F holders
- 75 funds
- $439.7B · +1 vs prior quarter
- Latest 8-K
- May 20, 2026
- Item 8.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Discovery, development, manufacturing, and marketing of human pharmaceutical products globally
- New emphasis on LillyDirect digital platform, growing portion of sales in 2025, expanding direct-to-patient access and partnerships
- Strategic shift to alternative product access via direct-to-patient and direct-to-employer channels to counteract unfavorable private sector payer dynamics
- Patent protection extends key products like Mounjaro to 2036-2040, with multiple patent term extensions and biologics data exclusivity through 2030s
- Noteworthy regulatory and market risk from counterfeit, misbranded, adulterated, and mass-compounded incretin products impacting safety and market integrity
Risk Factors
- Government price controls per Inflation Reduction Act causing Medicare drug price reductions for Jardiance (2026) and Trulicity, Verzenio (2028), accelerating revenue erosion
- U.S. market access risk from CVS Caremark removing preferred coverage for Zepbound on some insurance plans in July 2025
- Supply chain concentration with U.S. distribution reliant on limited wholesalers, risking disruptions if key wholesalers fail or delay payments
- Intense competition from multinational and Chinese pharmaceutical companies with accelerating R&D capabilities impacting market share and pricing
- Intellectual property risk from imminent patent expirations on key drug Trulicity and generic/biosimilar competition causing rapid revenue declines
Management Discussion & Analysis
- Revenue $65.2B in 2025, up 45% YoY from $45.0B in 2024, driven by Mounjaro and Zepbound volume growth
- Gross margin 83.0% in 2025 vs 81.3% in 2024; net income $20.6B (+95% YoY), EPS $22.95 (+96%)
- Best segment: Mounjaro revenue $23.0B (+99%) including $13.7B U.S.; worst segment: Other products down 1% to $22.9B
- Operating cash flow $16.8B in 2025 vs $8.8B prior year; capex $7.8B vs $5.1B; dividends $3.0B paid ($6/share); share repurchases $4.1B under $15B program
- Management expects near-term impact from regulatory approvals and U.S. Medicare access timing; key risks include evolving drug pricing policies and global trade tensions impacting margins and revenue
AI summary of the LLY 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $22,974 million, up 48% YoY from $15,558 million, driven by Mounjaro and Zepbound volume
- Net income $7,095 million, up 25% YoY from $5,661 million
- Mounjaro and Zepbound best-performing products, representing 65% of six-month revenue
- Foundayo launched in U.S.; Bridge Program discounted obesity medicines began July 1, 2026
- Near-term headwinds: pricing pressure, uncertain Medicare uptake, channel dynamics, tariffs, and counterfeit incretins
Risk Factors
- No material changes from December 31, 2025 Form 10-K risk factors
- Regulatory and compliance risks unchanged from the 2025 Form 10-K
- Operational and competitive risks unchanged from the 2025 Form 10-K
- Financial and liquidity risks unchanged from the 2025 Form 10-K
AI summary of the LLY 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- $9.0B debt offering completed, generating approximately $8.94B net proceeds for corporate funding
- Debt spans floating-rate notes due 2028–2029 and fixed-rate notes due 2029–2066
Item 5.07: Submission of Matters to a Vote of Security Holders
- 847.3M shares voted, representing approximately 90% of outstanding shares
- All four director nominees elected to three-year terms ending 2029
AI summaries of LLY 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for LLY
Don't miss the next LLY filing
- Alerts as it files. A push when LLY files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut LLY, by share count.
- Ask anything. An AI agent that reads every LLY filing and answers with sources.
LLY alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sulzberger Gabrielle | A | Sep 21, 2026 | 4.257 | $1164.89 |
| Alvarez Ralph | A | Sep 21, 2026 | 10.659 | $1164.89 |
| LUCIANO JUAN R | A | Sep 21, 2026 | 13.664 | $1164.89 |
| Fyrwald J Erik | A | Sep 21, 2026 | 8.513 | $1164.89 |
| Seymour Melissa | G | Sep 9, 2026 | 12 | - |
| Dozier Eric | G | Sep 2, 2026 | 216 | - |
| Hernandez Edgardo | G | Sep 2, 2026 | 13 | - |
| LUCIANO JUAN R | A | Aug 17, 2026 | 13.453 | $1183.16 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $34.1B | $45.0B | $65.2B | |
| Net Income | $5.2B | $10.6B | $20.6B | |
| Net Margin | 15.4% | 23.5% | 31.7% | |
| Balance Sheet | ||||
| Total Assets | $64.0B | $78.7B | $112.5B | |
| Equity | $10.8B | $14.2B | $26.5B | |
| ROE | 48.6% | 74.6% | 77.8% | |
| Per Share | ||||
| EPS | $5.80 | $11.71 | $22.95 | |
| Cash Flow | ||||
| Operating CF | $4.2B | $8.8B | $16.8B | |
Source: XBRL data in Lilly (Eli) (LLY)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate LLY share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 75 | $439.66B |
| Q1 2026 | 74 | $330.66B |
| Q4 2025 | 71 | $395.43B |
| Q3 2025 | 73 | $287.76B |
| Q2 2025 | 72 | $290.83B |
| Q1 2025 | 69 | $279.38B |
| Q4 2024 | 66 | $187.09B |
| Q3 2024 | 62 | $117.31B |
- FMR LLC (Fidelity)+2.12M (+8%)
- Goldman Sachs Group+1.31M (+21%)
- BlackRock+1.16M (+2%)
- Morgan Stanley+788.9K (+5%)
- Citadel Advisors LLC+703.7K (+291%)
- JPMorgan Chase & Co−1.10M (-8%)
- Fifth Third Bancorp−212.7K (-11%)
- D.E. Shaw & Co−140.8K (-22%)
- Marex Group plc−121.3K (-83%)
- Vanguard Portfolio Management LLC−117.8K (-1%)
- Blackstone Group+180
Source: 13F-HR filings on SEC EDGAR (aggregated from 562 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
LLY filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 22, 2026 | - | - | - |
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 10, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| SC 13D | Jul 30, 2026 | - | - | |
| SC 13G | Jul 24, 2026 | - | - | |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jul 21, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
LLY SEC filings: frequently asked questions
Are LLY insiders buying or selling?
In the last 90 days, Lilly (Eli) (LLY) officers, directors and 10% owners reported no open-market purchases and 3 open-market sales worth $16.0 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold LLY stock?
As of June 30, 2026, the largest Lilly (Eli) (LLY) holders among the 13F filers tracked by SignalX were BlackRock ($81.0 billion), Vanguard Capital Management LLC ($64.2 billion), PNC Financial Services ($61.6 billion), State Street Corp ($43.4 billion), FMR LLC (Fidelity) ($34.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was LLY's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Lilly (Eli) (LLY) reported revenue of $65.2 billion (up 44.7% from FY2024) and net income of $20.6 billion. Diluted EPS was $22.95. The figures come from the XBRL data in the 10-K.
What are the main risks in LLY's latest 10-K?
In the 10-K filed February 12, 2026, Lilly (Eli) (LLY) flagged: Government price controls per Inflation Reduction Act causing Medicare drug price reductions for Jardiance (2026) and Trulicity, Verzenio (2028), accelerating revenue erosion. U.S. market access risk from CVS Caremark removing preferred coverage for Zepbound on some insurance plans in July 2025. (AI summary of the Risk Factors section.)
What did LLY report in its latest 8-K?
Lilly (Eli) (LLY) filed an 8-K on May 20, 2026 reporting Item 8.01 (Other Events). $9.0B debt offering completed, generating approximately $8.94B net proceeds for corporate funding.
What are the latest LLY SEC filings?
Lilly (Eli) (LLY) filed its latest 10-K annual report on February 12, 2026, a 10-Q quarterly report on August 5, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on September 22, 2026.
What is LLY's SEC CIK number?
Lilly (Eli) (LLY)'s SEC Central Index Key (CIK) is 59478. EDGAR lists every LLY filing under that number.
Ask anything about LLY
The research agent reads LLY's filings, financials, insider trades and 13F holders, then answers with sources.